Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European Paediatric Soft-Tissue Sarcoma Study Group (EpSSG).

Journal of pediatric surgery·2026
Same author

Corrigendum to 'Radiotherapy and brachytherapy for cervical cancer : Recommendations of the Société française de radiothérapie oncologique' [Cancer Radiother 29 (2025) 104753].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

UNICURE-HD: A Multicentric Retrospective Cohort Study of Single-Insertion Image-Guided high-Dose-Rate Brachytherapy for Locally Advanced Cervical Cancer in the Context of Limited Brachytherapy Access in France.

International journal of radiation oncology, biology, physics·2026
Same author

Local Control of Bladder/Prostate Rhabdomyosarcoma: An Expert Consensus Guideline From the International Soft Tissue Sarcoma Consortium (INSTRuCT).

Pediatric blood & cancer·2026
Same author

The French Reirradiation Team for Research and Treatment (FReTREAT): A national collaborative model by Unitrad for advancing reirradiation research, education, and clinical practice in France.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same author

Prognostic significance of hypermetabolic contralateral cervical lymph node in patients with oral and oropharyngeal squamous cell carcinoma.

Journal of stomatology, oral and maxillofacial surgery·2026

Related Experiment Video

Updated: May 8, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Complications of chemotherapy, a basic science update.

Marianne Mazevet1, Maryline Moulin, Anna Llach-Martinez

  • 1Inserm UMR-S 769, LabEx Lermit-DHU Torino, université Paris-Sud, faculté de pharmacie, signalisation et physiopathologie cardiaque, 92296 Châtenay-Malabry cedex, France.

Presse Medicale (Paris, France : 1983)
|August 27, 2013
PubMed
Summary

Anthracyclines like doxorubicin are vital anticancer drugs but can cause heart failure. Research is exploring complex mechanisms beyond mitochondrial dysfunction to improve cancer treatment safety.

Related Experiment Videos

Last Updated: May 8, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Anthracyclines are effective anticancer agents treating various cancers.
  • Doxorubicin, a key anthracycline, can induce significant cardiotoxicity, potentially leading to heart failure.
  • Current understanding of doxorubicin-induced cardiotoxicity mechanisms is incomplete.

Purpose of the Study:

  • To review current knowledge on molecular mechanisms of doxorubicin-induced cardiotoxicity.
  • To explore potential new mechanisms involving signaling pathways beyond mitochondrial dysfunction.
  • To highlight the need for integrated research for improved cardioprotection strategies.

Main Methods:

  • Literature review of published research on doxorubicin cardiotoxicity.
  • Analysis of molecular mechanisms focusing on cardiomyocyte death, mitochondrial metabolism, and bioenergetics.
  • Exploration of signaling pathways like calcium homeostasis and cAMP cascade.

Main Results:

  • Mitochondrial dysfunction, oxidative stress, and cardiomyocyte death are established side effects.
  • Emerging evidence suggests alterations in calcium homeostasis and cAMP signaling pathways contribute to toxicity.
  • The mechanisms of cardiotoxicity are likely more complex than previously understood.

Conclusions:

  • Doxorubicin-induced cardiotoxicity involves intricate molecular pathways.
  • Further research integrating basic and clinical findings is crucial.
  • Developing novel diagnostic and therapeutic strategies with cardioprotection is essential for long-term cancer survivorship.